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The present study determines if (1) basal protein levels of nitric oxide (NO) synthases (eNOS, iNOS, and nNOS) are different in
cisplatin-sensitive (OV2008) and counterpart cisplatin-resistant (C13*) human ovarian cancer cells, (2) cisplatin alters NOS levels, (3)
NO donor causes apoptosis and p53 upregulation, (4) NO donor sensitises C13* cells to cisplatin via p53 upregulation (determined
by p53 siRNA gene-knockdown), and (5) inhibition of endogenous NOS alters cisplatin-induced apoptosis. Basal iNOS levels were
higher in OV2008 cells than in C13* cells. Cisplatin upregulated iNOS, but dramatically reduced eNOS and nNOS, in OV2008 cells
only. Failure of cisplatin to upregulate iNOS and downregulate eNOS/nNOS in cisplatin-resistant C13* cells may be an aetiological
factor in the development of resistance. The NO donor S-nitroso-N-acetylpenicillamine (SNAP) increased p53 protein levels and
induced apoptosis in both cell types, and enhanced cisplatin-induced apoptosis in C13* cells in a p53-dependent manner (i.e.,
enhancement blocked by p53 siRNA). Specific iNOS inhibitor 1400W partially blocked cisplatin-induced apoptosis in OV2008 cells.
In cisplatin-resistant C13* cells, blocking all NOSs with N
G-amino-L-arginine dramatically changed these cells from cisplatin-resistant to
cisplatin-sensitive, greatly potentiating cisplatin-induced apoptosis. The data suggest important roles for the three NOSs in regulating
chemoresistance to cisplatin in ovarian cancer cells.
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Cisplatin (CDDP) is a widely used first-line chemotherapeutic
agent for ovarian cancer (Siddik, 2003), and the induction of
apoptosis is a key determinant of CDDP sensitivity. Indeed, we and
others have demonstrated that failure of CDDP to induce apoptosis
is a major component of CDDP resistance (Sasaki et al, 2000; Yuan
et al, 2003; Fraser et al, 2003a). CDDP induces DNA crosslinks,
upregulation of p53, and subsequent p53-dependent apoptosis
(Siddik, 2003). However, in CDDP-resistant ovarian cancer cells,
failure to properly regulate p53 can contribute to the resistance
(Fraser et al, 2003a,b). Furthermore, basal activity of soluble
guanylyl cyclase (sGC), an intracellular receptor for nitric oxide
(NO), suppresses apoptosis in ovarian cancer cells, partly via
inhibition of p53 accumulation and activation (Fraser et al, 2006).
We hypothesised that basal sGC activity and regulation of p53 may
depend on endogenous NO formed by one of the three NO
synthases (NOSs), eNOS (also called NOS3), iNOS (also called
NOS2), or nNOS (also called NOS1) and that resistance to CDDP in
ovarian cancer cells may involve altered expression of the NOSs.
At high concentrations (typically 4100mM), NO donors
generate toxic concentrations of NO (e.g., 4100nM), inducing
apoptosis in many mammalian cells (Fiscus, 2002; Fiscus et al,
2002), including cancer cells (Wink et al, 1998). However, NO at
lower, more physiological levels (e.g., 1–20nM) often has the
opposite effect, preventing (or attenuating) the onset of apoptosis
in many mammalian cells, including lung fibroblasts (Wink et al,
1993), human B lymphocytes (Mannick et al, 1994), and many
normal and transformed neural cells (Fiscus, 2002; Fiscus et al,
2002). In most cells, the anti-apoptotic effects of low-level NO are
attributed to the stimulation of sGC with subsequent elevation of
cyclic guanosine monophosphate (cGMP) levels and increased
activation of protein kinase G (PKG). The anti-apoptotic role of
cGMP/PKG signalling pathway has been further established using
natriuretic peptides, atrial natriuretic peptide, and B-type/brain
natriuretic peptide (BNP), which activate cGMP/PKG via an
alternate pathway (i.e., activation of particulate guanylyl cyclase).
Atrial natriuretic peptide and BNP are exceptionally effective
inhibitors of stress-induced apoptosis in PC-12 phaeochromo-
cytoma and in NG108-15 neuroblastoma–glioma hybrid cells,
including suppressing the toxic/pro-apoptotic effects of high-level
NO (Fiscus et al, 2001; Cheng Chew et al, 2003). Even basal
levels of cGMP, generated primarily by basal sGC activity, and
subsequent partial activation of PKG are sufficient (in fact,
necessary) to prevent spontaneous apoptosis in certain
cells, including NG108-15 cells (Fiscus, 2002; Fiscus et al, 2002),
immortalised uterine epithelial cells (Chan and Fiscus, 2003), and
human ovarian cancer cells (Fraser et al, 2006). Because sGC is
activated by NO at very low concentrations (i.e., 50% of maximal
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ssGC activity stimulated by only 4nM NO; Bellamy et al, 2002), low
endogenous level of NO, generated by one of the three NOSs, may
be responsible for stimulating basal sGC activity and inhibiting
apoptosis in these cells.
Previously, melanoma cells (Tang and Grimm, 2004), transformed
b-cell line RINm5F (Tejedo et al, 2001), and transformed human
leukocytes (Mannick et al, 1997) were reported to generate
endogenous NO capable of suppressing apoptosis. Endogenous NO
is also believed to be responsible for aggressive tumour progression,
metastasis, and poor survival in cancer patients with tumours
exhibiting increased iNOS expression (Thomsen and Miles, 1998).
However, other studies focusing on ovarian cancer have shown that
overexpression of iNOS correlates with increased apoptosis (Son and
Hall, 2000; Rieder et al,2 0 0 1 ) .T h u s ,e n d o g e n o u sN Om a yc o n t r i b u t e
to either anti-apoptotic or pro-apoptotic effects in cancer cells,
most likely depending on cell type, local NO levels, source of NO
production, and other conditions (e.g., concurrent overproduction of
superoxide anion, which can combine with NO to form the toxic pro-
oxidant peroxynitrite) (Fiscus, 2002; Fiscus et al, 2002).
The present study determines whether eNOS, iNOS, and nNOS
are involved in regulating p53 accumulation and CDDP resistance
in ovarian cancer cells. CDDP-sensitive OV2008 cells and its
resistant variant C13* cells were used. Effects of NO donor and
NOS inhibitors on CDDP-induced p53 regulation and apoptosis
were also studied. Overall, the present study shows that all three
isoforms of NOS are expressed in both cell lines, but protein
levels are differentially regulated by CDDP in CDDP-sensitive and
CDDP-resistant cells. Furthermore, the data suggest that iNOS
contributes to CDDP-induced apoptosis in CDDP-sensitive cells,
whereas eNOS/nNOS contributes (in a p53-independent manner)
to chemoresistance by suppressing CDDP-induced apoptosis in
isogenic CDDP-resistant cells.
MATERIALS AND METHODS
Reagents
Chemicals were purchased from the following suppliers: Hoechst
33258, phenylmethlysulphonyl fluoride (PMSF), sodium orthovana-
date (Na3V04), and aprotinin (Sigma, St Louis, MO, USA); S-nitroso-
N-acetylpenicillamine (SNAP) and rabbit monoclonal anti-iNOS,
anti-eNOS, and anti-nNOS antibodies (Calbiochem-Novabiochem,
La Jolla, CA, USA); mouse monoclonal anti-p53, clone DO-1 (Santa
Cruz Biotechnologies, Santa Cruz, CA, USA); mouse monoclonal
anti-GAPDH antibody (ab8245) (Abcam, Cambridge, UK); p53-
siRNA (Cell Signaling Technology, Beverly, MA, USA); pre-stained
SDS-PAGE standards (Bio-Rad, Hercules, CA, USA); scrambled
control siRNA (Dharmacon, Lafayette, CO, USA); specific iNOS
inhibitor 1400W and general NOS inhibitor N
G-amino-L-arginine
(L-NAA) (Alexis Biochemicals, San Diego, CA, USA).
Cell lines and culture
Two counterpart human epithelial ovarian cancer cell lines,
OV2008 and C13* cells, were used. Cisplatin-sensitive OV2008
cells was derived from ovarian cystadenocarcinoma patient
without prior chemotherapy, and its CDDP-resistant variant
C13* was established after in vitro CDDP challenge. Wild-type
TP53 status of these cells has been previously demonstrated by
direct sequencing (Fraser et al, 2008). Cells were cultured as
described previously (Fraser et al, 2006).
Hoechst 33258 staining
Cells were handled and stained with Hoechst 33258 as previously
described (Fraser et al, 2006). Counting was carried out blinded to
sample identity, to reduce experimental bias.
Protein extraction and western blotting
Cells were pelleted and lysed in ice-cold lysis buffer (pH 7.4)
containing 50mM Hepes, 150mM NaCl, 1.5mM MgCl2,1m M EGTA,
100mM NaF, 10mM NaPPi, 10% glycerol, and 1% Triton X-100.
Protease inhibitors PMSF (1mM), aprotinin (125000IUml
1), and
Na3VO4 (1mM) were added to the lysis buffer freshly. Cell lysates
were sonicated briefly for three cycles (5s per cycle, 01C).
Sonicates were incubated on ice for 1h and pelleted by
centrifugation (15000g; 20min). Protein concentration was
determined using Bio-Rad DC Protein Assay Kits. Equal amounts
of proteins (50–100mg) were loaded and resolved by 15%
SDS-PAGE and electrotransferred (110V, 1h) onto nitrocellulose
membranes (Bio-Rad) as previously described (Fraser et al, 2006).
Membranes were blocked (at room temperature, 1h) with 5%
Blotto (Tris-HCl (10mM; pH 8.0), NaCl (150mM), Tween 20
(0.05%, v/v; TBS-Tween 20) containing skim milk (5%; w/v)), then
incubated overnight with primary antibodies iNOS, eNOS, nNOS,
and p53 (1:1000) or GAPDH (1:200000)), and subsequently with
the appropriate horseradish peroxidase-conjugated secondary
antibody (1:2000 in 5% Blotto; at room temperature for 1h).
The membranes were washed with TBS-Tween 20 thrice (15min
per wash), peroxidase activity was visualised with ECL reagent
(Amersham Biosciences), and exposed to Hyperfilm ECL (Amer-
sham Biosciences, Buckinghamshire, UK). Signal intensity was
determined densitometrically by Scion Image Software (version
4.02; Scion Corporation, Frederick, MD, USA).
RNA interference
After plating cells for 18h, 6ml of RiboJuice (Novagen, San Diego,
CA, USA) was added to 244ml of RPMI medium without serum.
The mixture was vortexed and incubated for 5min at room
temperature. After incubation, p53 siRNA (Cell Signaling Technology)
and control non-targeting siRNA (Dharmacon) at final concentra-
tion of 50nM were mixed with the transfection reagents. The
mixture was incubated at room temperature for 15min. During
this period, the culture media were removed from the cells and the
cells were washed once with PBS. The siRNA mixture was added in
drop by drop to each well to ensure maximal coverage, and an
additional 1250ml of complete media was added to bring the total
volume to 1.5ml. The cells were incubated for 6h and then the
media were removed and replaced with fresh, complete media for
24h. Downregulation was confirmed by western blot analysis.
Statistical analysis
Results are expressed as mean±s.e.m. of four or five independent
experiments. Statistical analysis was performed by one-way or two-
way ANOVA using PRISM software (Version 3.0; GraphPad,
San Diego, CA, USA). Bartlett’s tests were used to establish
homogeneity of variance on the basis of differences among s.d.
Differences between experimental groups were determined by
Bonferroni multiple comparison test. Po0.05 was considered to be
significant.
RESULTS
Basal iNOS, eNOS, and nNOS levels are different in
CDDP-sensitive (OV2008) cells than in CDDP-resistant
(C13*) cells and are differentially regulated by CDDP
in vitro
To assess the protein levels of basal and CDDP-induced NOS in
chemosensitive and chemoresistance cells, we cultured OV2008
ovarian cancer cells and the isogenic chemoresistant variant
C13* in the absence or presence of CDDP (0–10mM, 24h; DMSO
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scontrol) and evaluated iNOS, eNOS, and nNOS contents by western
blot. As shown in Figure 1A, basal iNOS levels in OV2008 cells are
significantly higher than those in C13* cells (Po0.05) and are
significantly upregulated by CDDP in the chemosensitive cells, but
not in the resistant variant cells (Po0.01). In contrast, basal eNOS
and nNOS levels in CDDP-sensitive OV2008 cells were significantly
(Po0.05) lower than in CDDP-resistant C13* cells (Figure 1B and
C) and were significantly downregulated after CDDP treatment
(Po0.01). As observed with iNOS, CDDP failed to significantly
alter eNOS and nNOS content in C13* cells, although a slight
downwards trend was observed. The data are consistent with the
hypothesis that iNOS, eNOS, and nNOS are differentially regulated
in chemosensitive (OV2008) and chemoresistant (C13) cells and
that CDDP resistance is associated with low iNOS content and high
levels of eNOS and nNOS in C13 cells, which are unresponsive to
CDDP.
Effects of a NO donor on p53 and CDDP sensitivity
Because we observed differential regulation of NOS isoforms in
chemosensitive and chemoresistant ovarian cancer cells, we next
asked whether NO itself could influence sensitivity to CDDP-
induced apoptosis. Moreover, as p53 is a key determinant of CDDP
sensitivity (Fraser et al, 2003b) and is regulated by the cGMP
pathway (Fraser et al, 2006), we also examined the effects of the
NO donor SNAP (Bellamy et al, 2002; Fiscus et al, 2002) on basal
and CDDP-induced p53 contents. OV2008 or C13* cells were
pretreated with SNAP for 24h, followed by treatment with CDDP
for a further 24h. As shown in Figure 2A, SNAP significantly
upregulated p53 content (Po0.05) and induced apoptosis
(Po0.01) in OV2008 cells. Interestingly, although CDDP alone
also upregulated p53 and induced apoptosis in these cells, co-
treatment with SNAP and CDDP resulted in a decrease in p53
content and no further increase in CDDP-induced apoptosis.
Similarly, in C13* cells, SNAP alone upregulated basal p53 and
induced apoptosis in C13* cells. However, in contrast to the
chemosensitive cells, pretreatment with SNAP facilitated
the CDDP-induced upregulation of p53 (Po0.01) and sensitised
the cells to CDDP-induced apoptosis (Po0.05) (Figure 2B). These
data suggest that high-level NO, released from an NO donor such
as SNAP (Bellamy et al, 2002; Fiscus et al, 2002), upregulates p53
and induces apoptosis in resistant ovarian cancer cells and
sensitises these cells to pro-apoptotic effects of CDDP.
p53 siRNA reduces NO donor-induced apoptosis in both
OV2008 and C13* cells and sensitises C13* cells to CDDP
We and others have demonstrated that p53 is an important
determinant of sensitivity to CDDP-induced apoptosis in ovarian
cancer cells. To test the role of p53 in the chemosensitising effects
of high concentrations of NO, we transfected chemosensitive and
chemoresistant cells with p53 siRNA and assessed the effects of p53
downregulation on SNAP-mediated sensitisation to CDDP-induced
apoptosis. As shown in Figure 3A, p53 levels were successfully
silenced by p53 siRNA, as compared with control siRNA
transfection in both OV2008 and C13* cells. Importantly, the
downregulation of p53 significantly attenuated SNAP-induced
apoptosis in both OV2008 and C13* cells (Po0.001 and Po0.01,
respectively), suggesting that high concentrations of NO induce
apoptosis in a p53-dependent manner.
To evaluate whether p53 is implicated in the sensitisation of cells
to CDDP-induced apoptosis by high concentrations of NO, we
transfected C13* cells with p53 siRNA (or control) followed by
treatment with SNAP and/or CDDP. As shown in Figure 3B and
consistent with the results shown in Figure 2B, SNAP sensitised
C13* cells to CDDP-induced apoptosis, and this was significantly
suppressed by the downregulation of p53 (Po0.001), suggesting
that p53 is necessary for NO donor-induced sensitisation to CDDP.
iNOS is required for CDDP-induced p53 accumulation and
apoptosis
We sought to assess whether iNOS is required for the pro-
apoptotic effects of CDDP. To that end, we treated OV2008 cells
with the specific iNOS inhibitor 1400W (Thomsen et al, 1997)
(100mM, 24h) and evaluated CDDP-induced p53 content and
apoptosis. As shown in Figure 4, 1400W partially blocked CDDP-
induced p53 accumulation. However, this effect was observed
only with higher concentrations of 1400W. In contrast, the pro-
apoptotic effects of CDDP were significantly reduced by both
higher and lower (10mM) concentrations of 1400W, suggesting that
CDDP-induced apoptosis is dependent on endogenous iNOS
activity.
Inhibition of all endogenous NOSs does not alter
CDDP-induced p53 content in CDDP-resistant C13* cells,
but sensitises them to CDDP
Because CDDP-resistant C13* cells show higher basal protein levels
of eNOS and nNOS and are resistant to CDDP-induced down-
regulation of eNOS and nNOS, we hypothesised that eNOS/nNOS
activity may play an important role in the resistance to CDDP in
C13* cells. To test this hypothesis, L-NAA, a general NOS inhibitor
that inhibits all three isoforms of NOS, was used (Reif and
McCreedy, 1995). Unlike 1400W, which is highly specific for iNOS,
none of the commercially available inhibitors of eNOS or nNOS are
highly specific. Thus, to effectively inhibit eNOS and nNOS in
CDDP-resistant C13* cells, we used the multitargeted NOS
inhibitor L-NAA.
Figure 5 shows western blot analysis of C13* cells pretreated
with L-NAA (0, 10, or 100mM) for 24h, followed by CDDP (0, 5, or
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Figure 1 Protein levels of iNOS, eNOS, and nNOS in cisplatin-sensitive
OV2008 and in cisplatin-resistant C13* cells were determined using
western blot analysis. (A) Basal iNOS levels were significantly higher in
OV2008 cells compared with C13* cells. Cisplatin (CDDP, 10mM,2 4 h )
significantly upregulated iNOS in OV2008, but not in C13* cells. (B and C)
Basal levels of eNOS and nNOS were significantly lower in OV2008 cells
compared with C13* cells. Cisplatin (5 and 10mM, 24h) significantly
downregulated both eNOS and nNOS in OV2008, but not in C13*, cells.
The bar graphs show mean±s.e.m. of protein levels of five independent
experiments. *Po0.05, compared with control (no cisplatin). **Po0.01,
compared with control (no cisplatin).
#Po0.05, comparing basal levels in
control OV2008 and in C13* cells.
##Po0.01, comparing basal levels in
control OV2008 and in C13* cells.
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Figure 2 (A) OV2008 cells were cultured with SNAP (0, 100, 200, 400mM) for 24h, followed by 5mM cisplatin (CDDP) for another 24h. p53 protein
content was assessed by western blot analysis. Results were normalised for protein loading by re-probing with anti-GAPDH antibody. Western blots are
representative of four independent experiments. Graphs show mean±s.e.m. of protein contents of four independent experiments. S-nitroso-N-
acetylpenicillamine alone (400mM,* Po0.05) increased basal p53 content, but decreased cisplatin-induced upregulation of p53 (**Po0.01) in chemosensitive
OV2008 cells. S-nitroso-N-acetylpenicillamine (400mM) alone significantly (**Po0.01) increased apoptosis. However, when used in combination with cisplatin,
SNAP did not further enhance cisplatin-induced apoptosis. (B) C13* cells were cultured with SNAP (0, 50, 100, 200, 400mM) for 24h, followed by 10mM
cisplatin for another 24h. Western blots are representative of five independent experiments. Graphs show mean±s.e.m. of p53 protein content and apoptosis
of five independent experiments. S-nitroso-N-acetylpenicillamine (200 and 400mM) alone significantly (***Po0.001) upregulated p53 levels. With cisplatin
co-treatment, SNAP at 50, 100, 200, and 400mM significantly (**Po0.01, ***Po0.001) increased p53 levels above control. p53 upregulation induced by SNAP
plus cisplatin was significantly (
##Po0.01) larger than with SNAP alone. S-nitroso-N-acetylpenicillamine (200 and 400mM) alone significantly (**Po0.01)
induced apoptosis and sensitised chemoresistant C13* cells to cisplatin-induced apoptosis (SNAP at 200mM,
#Po0.05).
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Figure 3 (A) Both OV2008 and C13* cells were transfected with p53-specific siRNA (50nM; scrambled sequence as control) for 24h, and subsequently
treated with 400mM SNAP for another 24h. Western blots are representative of four independent experiments. Graphs show mean±s.e.m. of
four independent experiments. Western blots show that p53 was successfully knocked down. *Po0.05, ***Po0.001, compared with SNAP treatment alone.
(B) C13* cells were transfected with p53-specific siRNA (50nM; scrambled sequence as control) for 24h, and subsequently treated with 200mM SNAP before
cisplatin (CDDP, 10mM) treatments for another 24h. Western blots are representative of four independent experiments and graphs show mean±s.e.m. from
four independent experiments. **Po0.01, compared with SNAP alone, ***Po0.001, compared with SNAP plus cisplatin (without siRNA).
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s10mM) for a further 24h. There was no significant effect of L-NAA
on p53 levels in any of the CDDP-treated groups, suggesting that
neither eNOS nor nNOS affect p53 content. In contrast, L-NAA
(both 10 and 100mM) dramatically enhanced the pro-apoptotic
effects of CDDP. These data suggest that low-level NO generated by
eNOS and nNOS contributes to the suppression of CDDP-induced
apoptosis in C13* cells.
DISCUSSION
The present study demonstrates that protein levels of the different
NOS isoforms or co-treatment with the NO donor SNAP regulates
induction of apoptosis and sensitisation to CDDP in human
ovarian cancer cells. CDDP upregulates iNOS protein levels and
markedly downregulates eNOS and nNOS protein levels in CDDP-
sensitive OV2008 cells but has no significant effect on the levels
of the three NOSs in CDDP-resistant C13* cells, suggesting that
differential regulation of the NOSs may contribute to CDDP
resistance. The data using NOS inhibitors suggest that iNOS
contributes to CDDP-induced apoptosis in OV2008 cells, whereas
eNOS/nNOS contributes to CDDP-resistant in C13* cells.
Endogenous NO is produced in mammalian cells by the three
NOSs, namely eNOS (NOS3), originally found constitutively
expressed in endothelial cells; iNOS (NOS2), first found to be
induced by cytokines in activated macrophages; and nNOS
(NOS1), originally discovered to be constitutively expressed in
neural cells (Forstermann et al, 1995; Fiscus, 2002; Fiscus et al,
2002). All of these NOS isozymes have now been found in many
other cell types. Typically, eNOS and nNOS produce NO at low or
physiological levels, which play important roles in the normal
regulation of the cardiovascular and neural systems (Fiscus, 2002;
Fiscus et al, 2002). Low-level NO (e.g., 1–20nM) binds to the heme
moiety of sGC, increasing its enzymatic activity, which in turn
results in the elevation of cGMP levels and increased activity of
PKG in mammalian cells. Stimulation of the sGC/cGMP/PKG
pathway by low-level NO contributes to cytoprotective/anti-
apoptotic effects in many types of mammalian cells (Fiscus,
2002; Fiscus et al, 2002). In contrast, iNOS typically produces
toxicity-associated NO. The toxicity may result from NO combin-
ing with superoxide anion, forming peroxynitrite, a powerful
oxidising substance that induces oxidative and nitrosative stress,
and apoptosis in mammalian cells (Fiscus, 2002; Fiscus et al, 2002).
The present study shows that all three isoforms of NOS are
expressed in human ovarian cancer cells and that the NOSs are
differentially expressed in CDDP-sensitive and CDDP-resistant
cells, suggesting potential involvement in chemoresistance.
Previous reports have demonstrated that pro-inflammatory
cytokines induced iNOS expression and apoptosis in ovarian
cancer cells (Son and Hall, 2000; Rieder et al, 2001). The current
study extends these findings by demonstrating that the pro-
apoptotic effects of iNOS may be mediated, in part, through a p53-
dependent pathway. This finding may have significant implications
with regard to the molecular mechanisms of chemosensitivity in
ovarian cancer cells, as p53 plays a key role in this process (Fraser
et al, 2003b). This hypothesis is further supported by the
observations that in normal human fibroblasts and liver epithelial
cells, iNOS induction stimulates p53 accumulation and apoptosis
(Forrester et al, 1996). Many tumour cells express higher levels of
iNOS and it is believed that NO generated by iNOS contributes to
p53 upregulation and induction of apoptosis in cancer cells (Ambs
et al, 1997). However, to date, reports showing direct functional
evidence linking NO, p53, and chemosensitivity in ovarian cancer
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apoptosis by Hoechst staining. Western blots are representative of four
independent experiments. Graphs show mean±s.e.m. of four independent
experiments. **Po0.01, ***Po0.001, compared with control.
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scells have been lacking. Thus, the present study represents the first
report directly demonstrating the role of p53 in high-level NO-
induced apoptosis (using siRNA gene knockdown) and the role of
the three endogenous NOSs in regulating sensitivity to CDDP in
ovarian cancer cells.
The present study shows that the NO donor SNAP, when used at
higher concentrations (200 and 400mM) that generate toxic levels
of NO, induces apoptosis in both CDDP-sensitive (OV2008) and
CDDP-resistant (C13*) ovarian cancer cells. Furthermore, SNAP
(50–400mM) caused concentration-dependent enhancement of
CDDP-induced p53 upregulation in C13* cells, sensitising these
cells to pro-apoptotic effects of CDDP. Gene knockdown with p53
siRNA prevented this sensitisation, demonstrating that high
concentrations of NO contribute to CDDP sensitivity through a
p53-dependent mechanism.
Although depletion of endogenous NO in melanoma cells by NO
scavengers enhanced CDDP-induced apoptosis and cell cycle arrest
in a p53-dependent manner (Tang and Grimm, 2004), a direct
connection between p53 and CDDP-induced apoptosis was not
established. The present study shows that CDDP sensitisation
induced by high levels of NO donor in ovarian cancer cells directly
involves p53 upregulation, illustrated by our p53 siRNA gene
knockdown experiments (Figure 3). In contrast, CDDP sensitisa-
tion induced by inhibition of all three forms of NOS in C13*
ovarian cancer cells (Figure 5) did not change p53 levels in ovarian
cancer cells. Thus, the role of p53 in CDDP sensitisation appears to
be different in melanoma and ovarian cancer cells.
Our data suggest that endogenous eNOS/nNOS activity in
ovarian cancer cells, especially CDDP-resistant cells, produces low-
level NO that protects them against induction of apoptosis, thus
contributing to resistance against CDDP. Although iNOS could
potentially also produce low-level NO favouring cytoprotection,
the role of iNOS in ovarian cancer cells appears to be different
from that of eNOS/nNOS; that is, iNOS contributes to, rather than
suppresses, CDDP-induced apoptosis. This difference may relate to
different localisation of the NOSs or different products generated
by the NOSs (e.g., eNOS/nNOS generating cytoprotective NO,
whereas iNOS generating cytotoxic forms of NO, such as
peroxynitrite). Further studies will be needed to fully elucidate
the different roles of the three NOSs in chemosensitive and
chemoresistant ovarian cancer cells.
Overall, our data suggest a novel role for different NOSs in the
regulation of apoptosis and sensitivity to CDDP in human ovarian
cancer cells. The three NOS isoforms are regulated differentially by
CDDP in CDDP-resistant and CDDP-sensitive ovarian cancer cells,
which may contribute to chemoresistance. Inhibition of all NOSs
in CDDP-resistant cells dramatically sensitises these cells to
CDDP-induced apoptosis. The data suggest potential new ways
of sensitising chemoresistant ovarian cancer cells to the thera-
peutic effects of CDDP.
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